MARKET INTEL |
PRIME CONTRACT

Purchase Order - W81XWH21P0021

OVERVIEW

Awardee
Original Description
MEDICAL RESEARCH AND DEVELOPMENT DHA SBIR PH I H202-002-0014
Place of Performance
College Station, TX USA
Pricing
Fixed Price
Set Aside
Small Business Set Aside - Total (SBA)
Extent Competed
Full And Open Competition After Exclusion Of Sources
Related Opportunity
HQ003420R2000

SBIR DETAILS

Research Type
Small Business Innovation Research Program (SBIR) Phase I
Title
Multiplexed, high-throughput functional assay to evaluate bactericidal activity of antibodies against Shigella
Abstract
Shigella infection is one of most common medical problems for deployed military personnel. Shigella infection causes acute diarrheal as well as chronic functional bowel disorders and reactive arthritis, and the infection keeps our service members out of fight, threatening unit readiness. Therefore, the need of prevention of Shigella infection has become a high priority for US Service Members. A safe and effective Shigella vaccine is therefore of paramount importance. Monitoring of Shigella vaccine effectiveness could be expedited and simplified by the ability to evaluate antibody activities. The bactericidal activity of Shigella antibodies has been used as a measure to evaluate the functional activity of antibodies. However, conventional bactericidal activity assay is based on counting the surviving bacterial forming units on plates through overnight culture, which is labor-sensitive, time-consuming, and not suitable for large-scale studies. To test the antibody against multiple serotypes, the assay must be performed on each serotype and large qualities of samples are needed. A multiplexed, high-throughput antibody bactericidal assay against an array of Shigella strains would enable large-scale sample analysis and support rapid vaccine development. Lynntech proposes to develop a rapid, high-throughput, and cost-effective multiplex assay capable of simultaneously evaluating bactericidal activity of antibodies against multiple Shigella serotypes. This assay is being designed to be simple and has the capability to provide sample-to-answer results in four hours. Furthermore, Lynntech's bactericidal assay can serve as a multiplex detection and qualification platform to evaluate bactericidal activity of antibodies without the need for culture.
Topic Code
DHA202-002
Solicitation Number
20.2
Contact
Dakota Burleson
(979) 764-2200
contract@lynntech.com

STATUS
(Complete)

Period of Performance

1/12/21

Start Date

10/11/21

Current End Date

10/11/21

Potential End Date
100% Complete

Obligations

$250.0K

Total Obligated

$250.0K

Current Award

$250.0K

Potential Award
100% Funded

AWARD RELATIONSHIPS

Purchase Order

W81XWH21P0021

Subcontracts

-

Purchase Order

W81XWH21P0021

Subs

-

ACTIVITY TIMELINE

SUBCONTRACT AWARDS

Opportunity Lifecycle

HISTORY

COMPETITION
Solicitation Procedures
Negotiated Proposal/Quote
Number of Offers Received
41
Other Than Full and Open Competition
None
Evaluated Preference
None
Commercial Item Acquisition
Commercial Item Procedures Not Used
Simplified Procedures for Commercial Items
No

OTHER CATEGORIZATIONS

Subcontracting Plan
Plan Not Required
National Interest Action
None
IT Commercial Item Category
Not Applicable
AGENCY DETAIL
Created By
teely.e.shaffer.civ.w81xwh@mail.mil
Last Modified By
teely.e.shaffer.civ.w81xwh@mail.mil
Approved By
teely.e.shaffer.civ.w81xwh@mail.mil
Awarding Office
W81XWH W4PZ USA MED RSCH ACQUIS ACT
Funding Office
W23RYX W03J USA MED RES AND DEV CMD

LEGISLATIVE MANDATES

Clinger-Cohen Act Compliant
No
Construction Wage Rate Requirements
Not Applicable
Labor Standards
Not Applicable
Materials, Supplies, Articles & Equipment
Not Applicable
Last Modified: 7/6/21


PIID: W81XWH-21-P-0021